Bayer Consumer Health’s Evendon-Challis On The ‘Huge Potential’ Of OTC Digital Therapeutics, AI

HBW Insight speaks to Bayer Consumer Health's head of R&D and chief scientific officer David Evendon-Challis about the opportunity presented by a new generation of OTC digital therapeutics as well as by AI-driven self-care.

• Source: Shutterstock

There’s been a “lot of talk about digital therapeutics within the consumer health industry,” with the excitement around this space “growing rapidly,” according to Bayer’s David Evendon-Challis.

“When there’s an opportunity for digital to not just be a health companion, which is useful in many instances, but actually to provide a service directly, that is really interesting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography